Title: Cystic FibrosisCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 7/6/2018 12:00:00 AM
Authors: Trigo Salado C, Leo Carnerero E, de la Cruz Ramírez MD Abstract The relationship between cystic fibrosis (CF) and the risk of developing inflammatory bowel disease (IBD) is not clear. CFTR mutations can influence dysbiosis and increased intestinal permeability, which are two key elements in the pathophysiology of IBD. These patients have increased intestinal inflammation, as demonstrated by increase pro-inflammatory gene expression in the bowel, specific fecal markers (fecal calprotectin), gross lesions (capsule endoscopy) and histological lesions on examination of surgical specimens. PMID: 3023...
We present a case of a 33-year-old male admitted to the hospital for a CF exacerbation who had an acute neurological decompensation due to an infarction of his right occipital and posterior temporal lobe.
ConclusionBeing HSP27 involved in several pathological conditions, including protein conformational diseases (i.e Cystic Fibrosis) and cancer, the need of drugs to modulate its activity is growing and CK2-targeting could represent a new strategy to reduce cellular HSP27 level.General significanceThis study identifies CK2 as a molecular target to control HSP27 cellular expression.
Conclusions: Infants receiving higher initial PERT dose demonstrate better weight-related outcomes, as reflected by attainment of favorable changes in WAZ and W/L%, at age 2 years.
Conclusions: RELiZORB use was found to be safe, well tolerated, and resulted in increased levels of FAs in RBCs and plasma. This is the first prospective study to show EN can improve FA abnormalities in CF. Because improvement in omega-3 levels has been shown to help pulmonary and inflammatory status as well as anthropometric parameters in CF, RELiZORB may have important long-term therapeutic benefits in patients with CF.
Publication date: Available online 18 September 2018Source: The LancetAuthor(s): Vikas Goyal, Keith Grimwood, Catherine A Byrnes, Peter S Morris, I Brent Masters, Robert S Ware, Gabrielle B McCallum, Michael J Binks, Julie M Marchant, Peter van Asperen, Kerry-Ann F O'Grady, Anita Champion, Helen M Buntain, Helen Petsky, Paul J Torzillo, Anne B ChangSummaryBackgroundAlthough amoxicillin–clavulanate is the recommended first-line empirical oral antibiotic treatment for non-severe exacerbations in children with bronchiectasis, azithromycin is also often prescribed for its convenient once-daily dosing. No randomised contr...
Publication date: Available online 19 September 2018Source: Microbial PathogenesisAuthor(s): Hizbullah, Zarghoona Nazir, Sahib Gul Afridi, Mohibullah Shah, Sulaiman Shams, Asifullah KhanAbstractThe Burkholderia pseudomallei is a unique bio-threat and causative agent of melioidosis. The B. pseudomallei Bp1651 strain has been isolated from a chronic cystic fibrosis patient. The genome-level DNA sequences information of this strain has recently been published. Unfortunately, there is no commercial vaccine available till date to combat B. pseudomallei infection. The genome-wide prioritization approaches are widely used for the...
In this article, the diagnosis, treatment, and impact of nontuberculous mycobacteria infection among patients with cystic fibrosis is discussed.Seminars in Respiratory and Critical Care Medicine
Hepatobiliary complications commonly occur in cystic fibrosis (CF) with increasing prevalence due to longer life expectancies and widespread screening efforts. CF-related liver disease (CFLD) is a term used to describe a spectrum of hepatic diseases in CF including cirrhosis and portal hypertension . Although regular screening by physical examination and liver enzyme level analysis (alanine transaminase (ALT) and aspartate transaminase (AST)) is widely performed, it is unclear whether these tools can predict patients who will develop CFLD or those who will progress to cirrhotic disease.
PMID: 30235006 [PubMed - as supplied by publisher]